The stock price of LTTS increased by 1.10% following the news of a collaboration with NVIDIA to develop a Gen AI and software-defined architecture for medical imaging in endoscopy. This joint development aims to create a scalable platform for the medical industry, featuring image processing pipeline, noise reduction, edge and contrast enhancement, and texture and color improvement.
The software-defined architecture is designed to enhance visualization for image processing and AI-based decision-making support, particularly in polyp detection and classification. Shanker Trivedi, Senior Vice President of Enterprise Business at NVIDIA, stated that the collaboration offers value to the medical technology industry by expediting the development of AI-enabled, software-defined medical devices.
At 11.40 am on the BSE, LTTS shares were trading up by 1.10% to ₹4,502.90.